SEC Tracker
Get the app
MRMD · XBRL financial data

Marimed financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MRMD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers38,80038,899*37,93340,43840,59139,002*37,95539,61140,76441,650*39,48141,925
Cost of revenue21,96221,582*21,46123,52923,81326,293*22,81723,57924,40131,148*24,20525,700
Gross profit16,83817,317*16,47216,90916,77812,709*15,13816,03216,36310,502*15,27616,225
General and administrative6,1356,612*6,1406,8046,1006,574*6,2506,3436,5926,957*6,8876,864
Total operating expenses13,54614,906*14,45115,95315,43814,114*15,98914,89114,76415,027*15,15115,807
Operating income (loss)3,2922,411*2,0219561,340(1,405)*(851)1,1411,599(4,525)*125418
Interest expense2,4821,558*1,6291,7241,7051,886*1,7621,7621,8252,153*1,9762,007
Other income (expense)(646)(79)*(20)(30)00*01719(753)*—0
Income tax expense (benefit)4,462509*1,6908666554,948*2,8316912,759(2,687)*2,6512,018
Net income (loss)(4,259)(10,169)*(1,298)(1,651)(1,011)(8,204)*(5,452)(1,269)(2,948)(4,631)*(3,785)(3,589)
Earnings per share, basic USD per share(0.01)(0.03)*0.000.000.00(0.02)*(0.01)0.00(0.01)(0.01)*(0.01)(0.01)
Earnings per share, diluted USD per share(0.01)(0.03)*0.000.000.00(0.02)*(0.01)0.00(0.01)(0.01)*(0.01)(0.01)
Weighted average shares, basic thousands of shares373,081376,005*375,211379,514380,599381,249*382,557389,903392,613395,300*397,450399,597
Weighted average shares, diluted thousands of shares373,081376,005*375,211379,514380,599381,249*382,557389,903392,613395,300*397,450399,597

Balance sheet

CSV

Fiscal quarters (MRMD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents13,25914,64515,23410,1929,7887,2827,2016,1386,5968,8847,9378,437
Short-term investments161880000——————
Accounts receivable6,3527,1996,4917,7447,3218,7429,1827,6887,9559,1149,4399,358
Inventory24,20625,30629,04431,13934,97533,48837,56038,82540,04036,60139,29636,675
Total current assets50,79251,43254,89553,05456,68053,50958,00257,13060,09359,29060,78858,433
Property and equipment, net85,19589,10390,76593,97795,49694,16794,39292,64691,25389,38588,05486,411
Right-of-use asset9,6799,7169,4569,2198,9778,7308,5258,2527,9737,7237,5397,662
Goodwill11,99311,99315,81215,81215,81215,81219,48220,05122,65524,00224,00224,002
Total assets190,817196,123201,332208,534212,681206,989208,000204,373205,599202,565201,185197,233
Accounts payable8,4949,00110,25611,85412,98313,18913,96911,21811,24114,58615,10913,147
Accrued liabilities5,3473,5494,6135,0486,2764,4357,7297,4129,0269,50910,3579,972
Total current liabilities35,29230,86235,45540,65944,59748,67855,30850,94456,58459,06763,75963,753
Lease liability, non-current8,4498,4558,2188,0037,7847,5497,2707,0456,8336,6166,3876,484
Total liabilities91,955107,209113,511120,931125,840128,113134,063131,200136,553137,831147,739147,056
Accumulated deficit(89,786)(99,955)(101,253)(102,904)(103,915)(112,119)(117,571)(118,840)(123,301)(127,932)(131,717)(135,306)
Total liabilities and equity190,817196,123201,332208,534212,681206,989208,000204,373205,599202,565201,185197,233
Common shares outstanding (cover page) thousands of shares376,122375,130379,644380,610381,306382,174389,230392,310395,074397,883399,266403,041

Cash flows

CSV

Fiscal quarters (MRMD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(4,259)(10,169)*(1,298)(1,651)(1,011)(8,204)*(5,452)(1,269)(2,948)(4,631)*(3,785)(3,589)
Stock-based compensation296*219*244248*280*278*547549*382*382*325350*
Net cash from operating activities7,900*3,234*3,2103,185*803*(413)*1,293297*2,676*3,429*9492,219*
Purchases of property and equipment5,963*5,381*3,3684,968*2,566*1,058*266309*559*33*373298*
Net cash from investing activities(6,215)*(6,348)*(4,266)(9,543)*(2,124)*(1,200)*(115)(554)*(514)*(197)*(753)(507)*
Net cash from financing activities(3,061)*4,500*1,6451,316*917*(893)*(1,259)(806)*(1,704)*(944)*(1,143)(1,212)*
Net change in cash(1,376)*1,386*589(5,042)*(404)*(2,506)*(81)(1,063)*458*2,288*(947)500*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Marimed8,43741,9252,219*403.0M— 10-QJun 30, 2026
vTv Therapeutics86,6430(11,443)*not reported7.6 quarters 10-QJun 30, 2026
Ovid Therapeutics11,327733(17,594)*195.3M6.7 quarters 10-QJun 30, 2026
Aptose Biosciences1,020not reported(5,841)2.6M0.2 quarters 10-QMar 31, 2026
Lisata Therapeutics10,4430(2,649)*9.0M3.9 quarters 10-QJun 30, 2026
Nanoviricides2,794not reported(2,122)*25.5M1.3 quarters 10-KJun 30, 2026
Tenax Therapeutics118,0000*(14,150)*37.4M8.3 quarters 10-QJun 30, 2026
Dare Bioscience12,618188(6,775)*15.3M1.9 quarters 10-QJun 30, 2026
Aytu Biopharma26,30816,106*4,406*10.9M— 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.